Form 4: SANUWAVE Health COO Peter Stegagno Exercises Stock Options and Sells Shares

SANUWAVE Health's Chief Operating Officer, Peter Stegagno, reported exercising stock options and subsequently selling a portion of his common stock holdings on June 5, 2025, as detailed in a recent SEC Form 4 filing.

Summary

• Peter Stegagno, Chief Operating Officer of SANUWAVE Health, Inc. (SNWV), reported equity transactions on June 5, 2025.
• He acquired 529 shares of common stock by exercising stock options at an exercise price of $22.50 per share.
• He also acquired an additional 1,333 shares of common stock by exercising stock options at an exercise price of $15.00 per share.
• Following these acquisitions, Mr. Stegagno disposed of 1,862 shares of common stock through a sale at a weighted-average price of $27.71 per share, with individual sale prices ranging from $27.59 to $27.82.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan.
• After these reported transactions, Mr. Stegagno's direct beneficial ownership of SANUWAVE Health common stock stands at 2,032 shares.

Sentiment

Score: 5

Explanation: Neutral. The filing reports routine insider transactions (option exercise and sale under a 10b5-1 plan). While a sale reduces insider ownership, it was pre-planned and the sale price was higher than the exercise price, indicating a profitable transaction for the insider. No new positive or negative company-specific news is conveyed that would significantly alter sentiment.

Positives

• The exercise of stock options indicates a prior commitment by the executive to acquire company equity.
• The sale price of $27.71 (weighted average) is significantly higher than both option exercise prices ($22.50 and $15.00), indicating a profitable transaction for the insider.

Negatives

• An insider sale, even if pre-planned under a Rule 10b5-1 plan, reduces the executive's direct equity stake in the company, which can sometimes be perceived as a slight reduction in alignment with shareholder interests.

Future Outlook

This Form 4 filing reports past insider transactions and does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• The filing includes a standard undertaking by the reporting person to provide full information regarding the number of shares sold at each separate price within the reported range upon request from the issuer, any securityholder of the issuer, or the staff of the Securities and Exchange Commission.

Industry Context

This filing is a routine insider transaction report and does not provide broader industry context. It reflects an individual executive's equity management rather than a strategic industry move or a reflection of industry trends.

Comparison to Industry Standards

• As a Form 4 filing, this document reports individual insider transactions and does not contain information suitable for comparison to industry-wide financial or operational benchmarks.
• It is a compliance filing under Section 16(a) of the Securities Exchange Act of 1934, detailing changes in beneficial ownership by an insider.

Stakeholder Impact

• Shareholders: The sale by a Chief Operating Officer, even if pre-planned, slightly reduces insider alignment, but the overall impact is likely minimal given the routine nature of such transactions under Rule 10b5-1 plans.

Next Steps

• The reporting person undertakes to provide additional details on the specific prices of shares sold within the reported range upon request from relevant parties.

Key Dates

Keywords

SANUWAVE Health, SNWV, Form 4, Insider Trading, Stock Options, Equity Sales, Peter Stegagno, Chief Operating Officer, Rule 10b5-1